메뉴 건너뛰기




Volumn 140, Issue 5, 2017, Pages

Intravenous zanamivir in hospitalized patients with influenza

(15)  Bradley, John S a   Blumer, Jeffrey L b   Romero, Jos R c   Michaels, Marian G d   Munoz, Flor M e   Kimberlin, David W f   Pahud, Barbara g   DeBiasi, Roberta L h   Yamamoto, Go i   Roberts, Grace j   Hossain, Mohammad j   Shortino, Denise k   Yates, Phillip J l   Adams, Bryan k   Peppercorn, Amanda j  


Author keywords

[No Author keywords available]

Indexed keywords

ZANAMIVIR; ANTIVIRUS AGENT;

EID: 85030626459     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2016-2727     Document Type: Article
Times cited : (25)

References (16)
  • 1
    • 79953881907 scopus 로고    scopus 로고
    • Statistical estimates of absenteeism attributable to seasonal and pandemic influenza from the Canadian Labour Force Survey
    • Schanzer DL, Zheng H, Gilmore J. Statistical estimates of absenteeism attributable to seasonal and pandemic influenza from the Canadian Labour Force Survey. BMC Infect Dis. 2011;11:90
    • (2011) BMC Infect Dis , vol.11 , pp. 90
    • Schanzer, D.L.1    Zheng, H.2    Gilmore, J.3
  • 2
  • 3
    • 84942875583 scopus 로고    scopus 로고
    • Recommendations for prevention and control of influenza in children 2015-2016
    • Committee on Infectious Diseases, American Academy of Pediatrics
    • Committee on Infectious Diseases, American Academy of Pediatrics. Recommendations for prevention and control of influenza in children, 2015-2016. Pediatrics. 2015;136(4): 792-808
    • (2015) Pediatrics , vol.136 , Issue.4 , pp. 792-808
  • 4
    • 84898618697 scopus 로고    scopus 로고
    • Zanamivir for influenza in adults and children: Systematic review of clinical study reports and summary of regulatory comments
    • Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2547
    • (2014) BMJ , vol.348 , pp. g2547
    • Heneghan, C.J.1    Onakpoya, I.2    Thompson, M.3    Spencer, E.A.4    Jones, M.5    Jefferson, T.6
  • 5
    • 85034092493 scopus 로고    scopus 로고
    • Revised 2016. Accessed August 1, 2016
    • GlaxoSmithKline. Relenza prescribing information. 2013. Revised 2016. Available at: https://www.gsksource. com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing-Information/Relenza/pdf/RELENZA-PI.pdf. Accessed August 1, 2016
    • (2013) GlaxoSmithKline. Relenza Prescribing Information
  • 6
    • 77956116079 scopus 로고    scopus 로고
    • Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays
    • Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother. 2010;54(9):3671-3677
    • (2010) Antimicrob Agents Chemother , vol.54 , Issue.9 , pp. 3671-3677
    • Nguyen, H.T.1    Sheu, T.G.2    Mishin, V.P.3    Klimov, A.I.4    Gubareva, L.V.5
  • 7
    • 84893290971 scopus 로고    scopus 로고
    • Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: An open-label, multicenter, singlearm, phase II study
    • Marty FM, Man CY, van der Horst C, et al. Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: An open-label, multicenter, singlearm, phase II study. J Infect Dis. 2014;209(4):542-550
    • (2014) J Infect Dis , vol.209 , Issue.4 , pp. 542-550
    • Marty, F.M.1    Man, C.Y.2    Van Der Horst, C.3
  • 8
    • 85009420566 scopus 로고    scopus 로고
    • Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: An international, randomised, double-blind, doubledummy, phase 3 trial
    • Marty FM, Vidal-Puigserver J, Clark C, et al. Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: An international, randomised, double-blind, doubledummy, phase 3 trial. Lancet Respir Med. 2017;5(2):135-146
    • (2017) Lancet Respir Med , vol.5 , Issue.2 , pp. 135-146
    • Marty, F.M.1    Vidal-Puigserver, J.2    Clark, C.3
  • 9
    • 85034042749 scopus 로고    scopus 로고
    • NIAID. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Accessed August 1, 2016
    • NIAID. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. 2014. Available at: http://rsc.Tech-res. com/docs/default-source/safety/daids-Ae-grading-Table-v2-nov2014.pdf. Accessed August 1, 2016
    • (2014)
  • 10
    • 79851471047 scopus 로고    scopus 로고
    • Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors
    • Pizzorno A, Bouhy X, Abed Y, Boivin G. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis. 2011;203(1):25-31
    • (2011) J Infect Dis , vol.203 , Issue.1 , pp. 25-31
    • Pizzorno, A.1    Bouhy, X.2    Abed, Y.3    Boivin, G.4
  • 11
    • 79955546685 scopus 로고    scopus 로고
    • Neuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virus
    • Naughtin M, Dyason JC, Mardy S, Sorn S, von Itzstein M, Buchy P. Neuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virus. Antimicrob Agents Chemother. 2011;55(5):2004-2010
    • (2011) Antimicrob Agents Chemother , vol.55 , Issue.5 , pp. 2004-2010
    • Naughtin, M.1    Dyason, J.C.2    Mardy, S.3    Sorn, S.4    Von Itzstein, M.5    Buchy, P.6
  • 12
    • 85034026071 scopus 로고    scopus 로고
    • WHO. Summary of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAI) Accessed February, 1, 2017
    • WHO. Summary of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAI). 2016. Available at: www.who. int/influenza/gisrs-laboratory/antiviral-susceptibility/avwg2014-nai-substitution-Table.pdf. Accessed February 1, 2017
    • (2016)
  • 13
    • 38949197905 scopus 로고    scopus 로고
    • Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario Canada
    • Toronto Invasive Bacterial Diseases Network
    • McGeer A, Green KA, Plevneshi A, et al; Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45(12): 1568-1575
    • (2007) Clin Infect Dis , vol.45 , Issue.12 , pp. 1568-1575
    • McGeer, A.1    Green, K.A.2    Plevneshi, A.3
  • 14
    • 84987920191 scopus 로고    scopus 로고
    • Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during a phase II study of intravenous zanamivir in hospitalised subjects
    • Yates PJ, Raimonde DS, Zhao HH, et al. Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during a phase II study of intravenous zanamivir in hospitalised subjects. Antiviral Res. 2016;134:144-152
    • (2016) Antiviral Res , vol.134 , pp. 144-152
    • Yates, P.J.1    Raimonde, D.S.2    Zhao, H.H.3
  • 15
    • 85034022209 scopus 로고    scopus 로고
    • Centers for Disease Control and Prevention. Flu vaccination coverage, United States 2013-14 influenza season. Accessed November 1, 2016
    • Centers for Disease Control and Prevention. Flu vaccination coverage, United States, 2013-14 influenza season. 2014. Available at: www.cdc. gov/flu/pdf/fluvaxview/vax-coverage-1314estimates.pdf. Accessed November 1, 2016
    • (2014)
  • 16
    • 48949089658 scopus 로고    scopus 로고
    • Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) 2008
    • Fiore AE, Shay DK, Broder K, et al; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008;57(RR-7):1-60
    • (2008) MMWR Recomm Rep , vol.57 , Issue.7 , pp. 1-60
    • Fiore, A.E.1    Shay, D.K.2    Broder, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.